Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Dodick, David W
| Class:Id | Person:9702355 |
|---|
| _displayName | Dodick, David W |
|---|
| _timestamp | 2020-09-30 14:57:38 |
|---|
| created | [InstanceEdit:9702388] Jassal, Bijay, 2020-09-30 |
|---|
| firstname | David W |
|---|
| initial | DW |
|---|
| surname | Dodick |
|---|
| (author) | [LiteratureReference:9702344] Fremanezumab for the Preventive Treatment of Chronic Migraine
[LiteratureReference:9702370] Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial
[LiteratureReference:9702371] Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
[LiteratureReference:9702386] Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
[LiteratureReference:9702799] The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
[LiteratureReference:9702840] Ubrogepant for the Treatment of Migraine |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Dodick, David W (9702355)